News and Trends 18 May 2023 8 rare diseases selected for gene therapy trial portfolio The Foundation for the National Institutes of Health (FNIH) says the Accelerating Medicines Partnership Bespoke Gene Therapy Consortium (AMP BGTC) has selected eight rare diseases for its clinical trial portfolio. This portfolio pioneers a novel approach to gene therapy development for rare diseases by demonstrating that manufacturing and testing standards can provide a streamlined approval […] May 18, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 18 May 2023 New epilepsy study could lead to new treatment options The mechanisms underlying the pathogenesis of epilepsy, a neurological disorder characterized by excessive electrical activity in the brain, remain unknown. Now, using a novel radiotracer, researchers from Japan have been able to offer insight into the role of AMPAR trafficking in epileptogenesis. The radio tracer is [11C]K-2, the first technology to visualize and quantify α-amino-3-hydroxy-5-methyl-4-isoxazole […] May 18, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 18 May 2023 Sania Therapeutics launches to advance neural circuit dysfunction medicines Sania Therapeutics, which develops genetic medicines for neural circuit dysfunction, has launched with the unveiling of its platforms at the American Society of Gene & Cell Therapy (ASGCT) conference. Sania Therapeutics’ approach combines the evolution of adeno-associated viruses (AAV) in human neural circuits, the fundamental components of the nervous system, and tuneable conditionally-activated ion channels. […] May 18, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 May 2023 Diagnosing inflammatory diseases with synthetic peptides Common inflammatory disorders such as ulcerative colitis and Crohn’s disease can be diagnosed or monitored by measuring the protein calprotectin in stool samples, while serum levels of calprotectin could be used to monitor the inflammation status in rheumatoid arthritis. Calprotectin concentrations in patient samples are typically determined using antibodies that bind and detect the protein, […] May 17, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 May 2023 Scribe and Prevail to accelerate CRISPR-based genetic medicines for neurological and neuromuscular diseases Scribe Therapeutics Inc., a company creating genetic medicines through its CRISPR by Design approach to genetic modification, has announced a strategic collaboration with Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company. The deal gives Prevail exclusive rights to Scribe Therapeutics’ CRISPR X-Editing (XE) technologies for the development of in vivo therapies directed […] May 17, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 17 May 2023 Six Norwegian companies leading the country’s biotech scene Best known for its folklore and tales of the Vikings, Norway’s landscape boasts postcard-like islands and the northern lights. In addition to ranking top as one of the happiest nations in the world, the country relies on sectors like oil and gas, hydropower and aquaculture to strengthen its economic growth. And of late, the biotech […] May 17, 2023 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 16 May 2023 Five advancements in brain tumor research over the past year In 2023, it is estimated that 24,810 adults in the U.S. will be diagnosed with a primary malignant tumor of the brain and spinal cord. There is currently no cure for brain tumors and current treatment options are mostly limited to surgery, radiation therapy and chemotherapy. However, there is a lot of research being conducted […] May 16, 2023 - 9 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Reports 16 May 2023Outsourcing in life science R&D today Learn how online platforms facilitate outsourcing in life science R&D. May 16, 2023 Share WhatsApp Twitter Linkedin Email
News and Trends 16 May 2023 LabGenius looks to create molecules with huge increase in tumor killing ability LabGenius, which uses machine learning (ML) for antibody discovery, has presented data in a poster presentation at the Protein Engineering and Biotherapeutics (PEGS) annual meeting. The data were from LabGenius’ T-cell engager (TCE) lead optimization platform, which delivered highly potent and efficacious single-domain antibodies with best-in-class killing selectivity. Optimizing antibody therapeutics across multiple properties is […] May 16, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 May 2023 Molsid developing rapid AMR test Start-up biomed Molsid is developing the first rapid test to detect the potential presence of antimicrobial resistance (AMR) directly in primary clinical samples. ORSET Group and PULSALYS, the SATT in Lyon, extended financing to the company in March 2023. This was followed by the signing of an i-DEMO contract with the French investment bank bpiFrance. […] May 16, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 May 2023 SiSaf siRNA therapy gets FDA designations to treat autosomal dominant osteopetrosis SiSaf Ltd, an RNA delivery and therapeutics company, has announced that SIS-101-ADO, its siRNA therapeutic for patients with autosomal dominant osteopetrosis Type 2 (ADO2), has been granted orphan drug designation by the U.S. FDA. Also, due to the serious manifestations of this rare skeletal disorder in children, SIS-101-ADO has been granted rare pediatric disease designation […] May 16, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 May 2023 Researchers’ mutation discovery offers new Alzheimer’s hope Alzheimer’s disease (AD) is a progressive neurodegenerative disorder affecting tens of millions of people worldwide, and it is the most common cause of dementia. Early-onset AD is typically associated with mutations in the genes APP, PSEN1, and PSEN2, leading to a more aggressive form of the disease with atypical symptoms. In contrast, the newly discovered […] May 16, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email